BioSpace News Archive

Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions.

Positron Corporation is pleased to announce that it has ordered five NeuSight PET-CT 64 slice scanners from cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter (AF).

On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.

Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, announced that it has raised EUR 17 million in the first closing of its Series A round.

Crossject provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics.

Bioz, Inc. is delighted to combine efforts with AMSBIO, a global life sciences supplier focused on providing high-quality reagents and services to support scientists and researchers in various fields, including cell biology, stem cell research, neuroscience, and cancer research.

Alvotech announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025 have elected to convert the principal and accrued interest into ordinary shares of Alvotech at the fixed conversion price of US$10.00 per share on the last scheduled conversion date prior to maturity, which is July 1, 2024.

BD (Becton, Dickinson and Company) announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.

TFF Pharmaceuticals, Inc. today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.